LIDE’s Translational Medicine platform enables us to establish many acquired drug-resistant PDX models. Most of these models are generated from biopsy samples, not surgery samples like most other CROs. Most surgery samples are treatment naïve at clinic, making biopsy samples the preferred choice for establishing mouse models or cell lines. LIDE's PDX models, established from biopsy samples that have already developed acquired drug resistant in the patient, is a more relevant choice for drug screening. The partial list is below but please contact us for the most up to date models.
With CR(Conditional Reprogramming) technology, we areable to establish PDX matching cell lines for drug screening, Pro-RNAi, CRISPR, luciferase labelling etc. 100+ PDX matching cell lines are available. Please reference that list here.
|Cancer Type||Drug Resistance||Genetic Alteration|
anti PD-1 ab
|Colorectal Cancer||Avastin||KRAS: G12C
|Gastric Cancer||Herceptin||HER2: ampli
|Brain Cancer||/||EGFR: VIII
|Melanoma||anti PD-1 ab||BRAF: V600E|
Table: LIDE PDX models with drug resistance